Drug General Information
Drug ID
D0F3NH
Former ID
DIB012779
Drug Name
Balaglitazone
Synonyms
DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
Drug Type
Small molecular drug
Indication Type 1 diabetes [ICD9: 250; ICD10:E10] Phase 3 [522085]
Company
Dr Reddy's Research Foundation
Structure
Download
2D MOL

3D MOL

Formula
C20H17N3O4S
Canonical SMILES
n1(c(=O)c2c(nc1COc1ccc(CC3C(=O)NC(=O)S3)cc1)cccc2)C
CAS Number
CAS 199113-98-9
PubChem Compound ID
Target and Pathway
Target(s) Peroxisome proliferator activated receptor gamma Target Info Modulator
KEGG Pathway PPAR signaling pathway
AMPK signaling pathway
Osteoclast differentiation
Huntington's disease
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway CCKR signaling map ST
Pathway Interaction Database Noncanonical Wnt signaling pathway
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Signaling events mediated by HDAC Class I
RXR and RAR heterodimerization with other nuclear receptor
Regulation of retinoblastoma protein
Reactome PPARA activates gene expression
Transcriptional regulation of white adipocyte differentiation
Nuclear Receptor transcription pathway
WikiPathways Wnt Signaling Pathway Netpath
Nuclear Receptors in Lipid Metabolism and Toxicity
Differentiation of white and brown adipocyte
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Transcriptional Regulation of White Adipocyte Differentiation
Adipogenesis
SREBP signalling
Nuclear Receptors
References
Ref 522085ClinicalTrials.gov (NCT00515632) Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy. U.S. National Institutes of Health.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.